--- title: "ProImmune 推出 “掌握免疫力 2026”——上海研讨会，旨在解决关键的免疫原性挑战" type: "News" locale: "zh-CN" url: "https://longbridge.com/zh-CN/news/273211867.md" description: "ProImmune Ltd 宣布将于 2026 年 4 月 13-14 日在上海东方滨江酒店举办 “掌握免疫力 2026” 研讨会。此次首届活动将聚焦于药物开发中的免疫原性挑战，邀请全球生物治疗领域的领导者和监管机构的专家参与。研讨会旨在提供管理免疫原性风险的实用指导，这些风险可能对药物项目的成功产生重大影响。知名演讲者包括来自 FDA、辉瑞和罗氏的专家。该活动被视为中国生物制药行业从业者的必 attend 会议" datetime: "2026-01-21T10:05:39.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/273211867.md) - [en](https://longbridge.com/en/news/273211867.md) - [zh-HK](https://longbridge.com/zh-HK/news/273211867.md) --- > 支持的语言: [English](https://longbridge.com/en/news/273211867.md) | [繁體中文](https://longbridge.com/zh-HK/news/273211867.md) # ProImmune 推出 “掌握免疫力 2026”——上海研讨会，旨在解决关键的免疫原性挑战 **ProImmune Introduces Mastering Immunity 2026 - Shanghai Symposium to Address Key Immunogenicity Challenges** - _Symposium brings together global leaders in immunogenicity to connect with China’s rapidly evolving pharmaceutical development landscape_ - _Speakers include thought leaders in biotherapeutics, complex peptide drug developers, and regulatory authorities_ - _In-person event taking place at Oriental Riverside Hotel, Shanghai, 13-14 April 2026_ ProImmune Ltd, a global leader in immunological reagents and services, announced the launch of Mastering Immunity 2026 – Shanghai, an inaugural symposium in China providing practical, real-world guidance to help drug developers manage immunogenicity risk. Taking place at the Oriental Riverside Hotel in Shanghai, the event will convene leading scientists, industry executives, and regulatory professionals from around the world. Immunogenicity, the potential for biologics to trigger unwanted immune responses, remains a decisive factor in determining safety, efficacy, and regulatory and commercial success. When immunogenicity is poorly understood or assessed inadequately, development programs face clinical failure, costly redesigns, and significant delays. In some cases, these risks can lead to the loss of entire programs, representing financial impacts in the hundreds of millions or even billions of dollars, as well as extended timelines required for additional studies or reformulation. Presentations will cover modality-specific insights based on real world examples for emerging therapeutic platforms and perspectives on evolving global regulatory expectations presented by speakers from leading companies and regulators with experience of bringing successful drugs to market, including: - Dr. Zuben Sauna (Director, Center for Biologics Evaluation and Research, FDA) - Dr. Sophie Tourdot (Immunogenicity Sciences Lead, Pfizer) - Dr. Balaji MR (Vice President and Head – Non Clinical, Dr. Reddy’s Laboratories) - Dr. Daniela Verthelyi (Former Chief, Laboratory of Immunology, Office of Biotechnology Products, FDA) - Dr. Tim Hickling (Former Head of Immunosafety, Roche, Quasor) - Dr. Kanthikiran Varanasi (Global Head of Clinical Affairs, Galencium) - Andreas Hollenstein (Senior Principal Scientist, Immunosafety, Roche) - Dr. Nitinkumar Dobaria (Associate Director, Injectables Product Development, Lupin) - Dr. Anuj Saini (Global Head-Global Clinical Management, Dr Reddy’s Laboratories) - Prof. Yoonjoo Choi (Professor, Department of Microbiology and Immunology, Chonnam National University Medical School) **Dr. Juhao Yang, Toxicology Project Leader, China Innovation Center of Roche shared:** _"This meeting is a pivotal moment, bringing together global leaders to tackle the urgent challenge of immunogenicity risk and drive better patient outcomes. This is a must-attend event for anyone committed to shaping the future of biotherapeutics.”_ **Dr. Nikolai Schwabe, Chief Executive Officer, ProImmune, added:** “_Licensing activity and clinical trials are at an all-time high in China’s biopharmaceutical industry, but the regulatory landscape is still evolving. By connecting immunogenicity leaders from around the world to share experiences including development and regulatory best practice, ProImmune is playing a critical role in helping developers manage the risk around immunological effects and ultimately accelerate the development of successful therapeutic products.__”_ For event details and registration, including early-bird, visit: https://www.proimmune.com/mastering-immunity-2026-shanghai **Media Contact** Francesca Wallace Zyme Communications Email: francesca.wallace@zymecommunications.com View source version on businesswire.com: https://www.businesswire.com/news/home/20260121510655/en/ ### 相关股票 - [罗氏(ADR) (RHHBY.US)](https://longbridge.com/zh-CN/quote/RHHBY.US.md) - [标普全球医疗股指数 ETF - iShares (IXJ.US)](https://longbridge.com/zh-CN/quote/IXJ.US.md) - [生物科技 ETF - VanEck Vectors (BBH.US)](https://longbridge.com/zh-CN/quote/BBH.US.md) - [标普生物技术 ETF - SPDR (XBI.US)](https://longbridge.com/zh-CN/quote/XBI.US.md) - [美国制药 ETF - iShares (IHE.US)](https://longbridge.com/zh-CN/quote/IHE.US.md) - [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-CN/quote/IBBQ.US.md) - [医疗业 ETF - SPDR (XLV.US)](https://longbridge.com/zh-CN/quote/XLV.US.md) - [纳斯达克生物科技指数 ETF - iShares Nasdaq (IBB.US)](https://longbridge.com/zh-CN/quote/IBB.US.md) - [辉瑞 (PFE.US)](https://longbridge.com/zh-CN/quote/PFE.US.md) - [医药突破 ETF - ALPS (SBIO.US)](https://longbridge.com/zh-CN/quote/SBIO.US.md) - [2 倍做多纳斯达克生物技术 ETF - ProShares (BIB.US)](https://longbridge.com/zh-CN/quote/BIB.US.md) - [动态生物技术与基因组 ETF - Invesco (PBE.US)](https://longbridge.com/zh-CN/quote/PBE.US.md) - [基因改革 ETF - ARK (ARKG.US)](https://longbridge.com/zh-CN/quote/ARKG.US.md) - [纽交所高增长板生物技术指数 ETF - First Trust (FBT.US)](https://longbridge.com/zh-CN/quote/FBT.US.md) - [Immuneering (IMRX.US)](https://longbridge.com/zh-CN/quote/IMRX.US.md) - [医疗业 ETF - Vanguard (VHT.US)](https://longbridge.com/zh-CN/quote/VHT.US.md) ## 相关资讯与研究 - [减肥药市场迎来重磅玩家！多款在研药物傍身 罗氏誓言挤进全球前三](https://longbridge.com/zh-CN/news/277590823.md) - [FDA 要求开展 III 期试验 uniQure 亨廷顿病基因疗法上市受阻股价重挫约 33%](https://longbridge.com/zh-CN/news/277546905.md) - [德琪医药-B 与优时比就 ATG-201 达成全球独家授权协议](https://longbridge.com/zh-CN/news/277686682.md) - [礼来新药 “来瑞奇珠单抗” 在华申报上市 2025 年全球销售额达 4 亿美元](https://longbridge.com/zh-CN/news/277590520.md) - [FDA 瞄准 GLP-1 复方药物广告](https://longbridge.com/zh-CN/news/277789475.md)